IRCT20111206008307N45招募中3 期
Evaluation Effects of Dapagliflozin and Empagliflozin in Nondiabetic Patients with Left Ventricular Systolic Dysfunction following ST Elevation Myocardial Infarction : A Randomized Clinical Trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Heart Failure with Reduced Ejection Fraction
- •Aged 18 to 80 years
- •Consented patients
排除标准
- •Liver failure
- •Renal failure (estimated glomerular filtration rate less than 30 ml/min)
- •Patients with a history of taking dapagliflozin or empagliflozin
- •Diabetes mellitus
- •Contraindications of dapagliflozin or empagliflozin
- •Inflammatory and autoimmune diseases
- •Systolic blood pressure less than 100 or more than 180 mm Hg
- •Symptomatic hypotension
研究者
相似试验
已完成
不适用
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trialtype 2 diabetes mellitus, NAFLD, NASHJPRN-UMIN000030548Saitama Medical University Hospital100
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
尚未招募
4 期
Comparison of Dapagliflozin and Pioglitazone for Non-Alcoholic Fatty Liver Disease in Type 2 DiabetesCTRI/2024/07/071087Babra
已完成
不适用
A study to learn more about how dapagliflozin affects body fat levels compared to glimepiride in patients with type 2 diabetes who are taking metformiEndocrine, nutritional and metabolic diseaseKCT0003600AstraZeneca Korea160
尚未招募
不适用
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R